MX2012006691A - Nuevos conjugados y composiciones para inmunoterapia y tratamiento antitumoral. - Google Patents

Nuevos conjugados y composiciones para inmunoterapia y tratamiento antitumoral.

Info

Publication number
MX2012006691A
MX2012006691A MX2012006691A MX2012006691A MX2012006691A MX 2012006691 A MX2012006691 A MX 2012006691A MX 2012006691 A MX2012006691 A MX 2012006691A MX 2012006691 A MX2012006691 A MX 2012006691A MX 2012006691 A MX2012006691 A MX 2012006691A
Authority
MX
Mexico
Prior art keywords
functionally equivalent
identity
fusion protein
cells
polypeptide
Prior art date
Application number
MX2012006691A
Other languages
English (en)
Spanish (es)
Inventor
Ignacio Javier Melero Bermejo
Pedro Berraondo Lopez
Jessica Fioravanti
Jose Medina Echeverz
Maria Del Carmen Ochoa Nieto
Francisco De Asis Palazon Garcia
Silvia Bulfone-Paus
Hans Duitman Erwin
Original Assignee
Res Ct Borstel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by Res Ct Borstel filed Critical Res Ct Borstel
Publication of MX2012006691A publication Critical patent/MX2012006691A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5443IL-15
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2012006691A 2009-12-11 2010-12-10 Nuevos conjugados y composiciones para inmunoterapia y tratamiento antitumoral. MX2012006691A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ES201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (1)

Publication Number Publication Date
MX2012006691A true MX2012006691A (es) 2013-02-26

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006691A MX2012006691A (es) 2009-12-11 2010-12-10 Nuevos conjugados y composiciones para inmunoterapia y tratamiento antitumoral.

Country Status (11)

Country Link
US (1) US8771664B2 (enExample)
EP (1) EP2511294B1 (enExample)
JP (1) JP5784626B2 (enExample)
CN (1) CN102753574B (enExample)
AU (1) AU2010329805B2 (enExample)
BR (1) BR112012013868A8 (enExample)
CA (1) CA2783876C (enExample)
ES (1) ES2463016T3 (enExample)
MX (1) MX2012006691A (enExample)
RU (1) RU2597989C2 (enExample)
WO (1) WO2011070214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2989085T3 (es) 2011-01-18 2024-11-25 Bioniz Therapeutics Inc Composiciones para modular la actividad de citoquinas gamma-c
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP4032540A1 (en) * 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US10777298B2 (en) 2013-10-13 2020-09-15 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
HUE057917T2 (hu) * 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
US20180155439A1 (en) 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
DK3359556T3 (en) 2015-10-09 2021-08-30 Bioniz Llc Modulering af gamma-c-cytokinaktivitet
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス, インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
EP3976182A4 (en) 2019-05-03 2023-01-18 Bioniz, LLC MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS
US20250281583A1 (en) * 2021-10-13 2025-09-11 Modernatx, Inc. Composition of mrna-encoded il15 fusion proteins and methods of use thereof
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
DK0814838T3 (da) 1995-03-08 2003-09-15 Scripps Research Inst Antigenpræsenterende system og aktivering af T-celler
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
EP1718282A4 (en) 2004-01-15 2010-07-14 Sinai School Medicine PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US9139611B2 (en) 2006-07-13 2015-09-22 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos

Also Published As

Publication number Publication date
CN102753574A (zh) 2012-10-24
RU2012129208A (ru) 2014-01-20
AU2010329805B2 (en) 2016-07-14
US20120244118A1 (en) 2012-09-27
CN102753574B (zh) 2015-05-20
WO2011070214A3 (es) 2011-08-04
AU2010329805A1 (en) 2012-07-05
CA2783876A1 (en) 2011-06-16
CA2783876C (en) 2018-04-03
WO2011070214A8 (es) 2011-09-29
BR112012013868A2 (pt) 2017-01-10
EP2511294A2 (en) 2012-10-17
WO2011070214A2 (es) 2011-06-16
ES2463016T3 (es) 2014-05-27
US8771664B2 (en) 2014-07-08
JP5784626B2 (ja) 2015-09-24
BR112012013868A8 (pt) 2017-12-26
JP2013513377A (ja) 2013-04-22
EP2511294B1 (en) 2014-02-26
RU2597989C2 (ru) 2016-09-20

Similar Documents

Publication Publication Date Title
ES2463016T3 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
JP7250790B2 (ja) Il-2ムテインおよびその使用
ES2518393T3 (es) Moléculas de fusión y variantes de IL-15
ES2268863T3 (es) Receptores quimericos.
ES2399088T3 (es) Polipéptidos y ácidos nucleicos inmunosupresores
US20050158831A1 (en) Multimeric fusion proteins of TNF superfamily ligands
AU733719B2 (en) Improved vaccines
US20200397877A1 (en) Enhancing t cell activation using altered mhc-peptide ligands
KR20160016725A (ko) 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
US20110076304A1 (en) Adapter molecule for the delivery of adenovirus vectors
WO2018162450A1 (en) New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP2374813A1 (en) Use of phenol-soluble modulins for vaccine development
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.

Legal Events

Date Code Title Description
FG Grant or registration